StockMirror — Stock Screener

SUNPHARMA Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Sun Pharma reported Q2 FY27 revenue of INR161,000 million, up 11.8% YoY, with gross margin at 80.8% (higher YoY on better mix and favorable currency). EBITDA grew 4.8% to INR47,439 million but margins declined YoY to 29.3% due to lenalidomide benefit in base quarter. Adjusted PAT was INR31,620 million (reported PAT INR19,885 million after exceptional items). India business grew 17.3% with market share gain to 8.6%; US declined 8.2% YoY on lenalidomide erosion but grew 6.5% QoQ. Emerging Markets grew 7.6%. Innovative Medicines up 6.9% to USD356 million but Ilumya US slowed. R&D at 4.8% of sales, expected to ramp to 6-7% full-year. Organon acquisition on track for Q4 FY27 close. FY27 guidance maintained at high single-digit growth. Key concerns: Ilumya US recovery timeline unclear, no guidance upgrade despite strong H1, acquisition costs and financing details still emerging.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes revenue growth with high single-digit FY27 guidance while investing in R&D pipeline (6-7% of sales) and Organon integration. Margin focus evident in gross margin improvement (80.8%) through better product mix and cost management. However, near-term margins impacted by one-offs

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited (SUNPHARMA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More